Clinical trials: Recurrent Intraocular Melanoma
Brain and Central Nervous System Tumors, Intraocular Melanoma
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00003022
- Testing
- iodine I 131 monoclonal antibody 3F8
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body.
- Conditions
- Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma
- Trial name
- NBM-BMX-UM (NCT07136181)
- Testing
- NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novelwise Pharmaceutical Corporation
Intraocular Melanoma, Metastatic Cancer
Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
RATIONALE: Drugs used in chemotherapy, such as fotemustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00110123
- Testing
- fotemustine, isolated perfusion
- Where
- 8 sites in Italy, Poland and 2 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral…
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- ON-5001 (NCT06022029)
- Testing
- ONM-501, Cemiplimab
- Where
- 16 sites in United States, Australia
- Volunteers
- 168 people
- Sponsor
- OncoNano Medicine, Inc.
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with GM-CSF, CpG 7909, and incomplete Freund's adjuvant may make a stronger immune…
- Conditions
- Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
- Trial name
- NCT00471471
- Testing
- Peptide vaccine, GM-CSF, PF3512676
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Ahmad Tarhini
Metastatic Melanoma
Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01005472
- Testing
- sunitinib malate, temozolomide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Refractory Cancer, Recurrent Cancer
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma…
- Conditions
- Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
- Trial name
- ACTengine (NCT03686124)
- Testing
- IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product
- Where
- 21 sites in United States, Germany
- Volunteers
- 375 people
- Sponsor
- Immatics US, Inc.
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
This pilot clinical trial studies radioembolization and ipilimumab in treating patients with uveal melanoma with liver metastases.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma
- Trial name
- NCT01730157
- Testing
- ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Uveal Melanoma
Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study
The goal of this prospective observational study is to learn about patient quality of life and experience and medical information needs during uveal melanoma post-treatment surveillance.
- Trial name
- SALOME Quali (NCT06073548)
- Testing
- Questionnaires and interviews
- Volunteers
- 250 people
- Sponsor
- Institut Curie
Intraocular Melanoma, Melanoma (Skin)
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00238329
- Testing
- PEG-interferon alfa-2b, thalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Cancer
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as thrombopoietin and G-CSF may increase the number of immune cells found in…
- Trial name
- NCT00003597
- Testing
- recombinant human thrombopoietin, carboplatin, etoposide
- Where
- 24 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Children's Oncology Group
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00025181
- Testing
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response that will kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating white blood…
- Trial name
- NCT00003339
- Testing
- gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Southern California
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
This randomized phase II trial studies temozolomide to see how well it works compared to selumetinib in treating patients with melanoma of the eye that has spread to other places in the body.
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Uveal Melanoma
- Trial name
- NCT01143402
- Testing
- Dacarbazine, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 33 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
RATIONALE: Drugs used in chemotherapy, such as dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Recurrent Intraocular Melanoma
- Trial name
- NCT01100528
- Testing
- recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Case Comprehensive Cancer Center
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
This phase II trial is studying how well VEGF Trap works in treating patients with recurrent stage III or stage IV melanoma that cannot be removed by surgery.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma
- Trial name
- NCT00450255
- Testing
- ziv-aflibercept, pharmacological study
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Vaccine Therapy in Treating Patients With Advanced Melanoma
RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.
- Conditions
- Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
- Trial name
- Mel48 (NCT00705640)
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Craig L Slingluff, Jr